JP2019518460A - 操作されたＴｒｅｇ細胞 - Google Patents

操作されたＴｒｅｇ細胞 Download PDF

Info

Publication number
JP2019518460A
JP2019518460A JP2018565336A JP2018565336A JP2019518460A JP 2019518460 A JP2019518460 A JP 2019518460A JP 2018565336 A JP2018565336 A JP 2018565336A JP 2018565336 A JP2018565336 A JP 2018565336A JP 2019518460 A JP2019518460 A JP 2019518460A
Authority
JP
Japan
Prior art keywords
cells
cell
regulatory
foxp3
engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018565336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518460A5 (enExample
Inventor
アレクサンダー ワイ． ルデンスキー，
アレクサンダー ワイ． ルデンスキー，
孝敏 知念
孝敏 知念
Original Assignee
メモリアル スローン ケタリング キャンサー センター
メモリアル スローン ケタリング キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, メモリアル スローン ケタリング キャンサー センター filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2019518460A publication Critical patent/JP2019518460A/ja
Publication of JP2019518460A5 publication Critical patent/JP2019518460A5/ja
Priority to JP2022021158A priority Critical patent/JP2022058995A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
JP2018565336A 2016-06-16 2017-06-15 操作されたＴｒｅｇ細胞 Withdrawn JP2019518460A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022021158A JP2022058995A (ja) 2016-06-16 2022-02-15 操作されたＴｒｅｇ細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351104P 2016-06-16 2016-06-16
US62/351,104 2016-06-16
PCT/US2017/037794 WO2017218850A1 (en) 2016-06-16 2017-06-15 Engineered treg cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022021158A Division JP2022058995A (ja) 2016-06-16 2022-02-15 操作されたＴｒｅｇ細胞

Publications (2)

Publication Number Publication Date
JP2019518460A true JP2019518460A (ja) 2019-07-04
JP2019518460A5 JP2019518460A5 (enExample) 2020-07-27

Family

ID=60663377

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018565336A Withdrawn JP2019518460A (ja) 2016-06-16 2017-06-15 操作されたＴｒｅｇ細胞
JP2022021158A Pending JP2022058995A (ja) 2016-06-16 2022-02-15 操作されたＴｒｅｇ細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022021158A Pending JP2022058995A (ja) 2016-06-16 2022-02-15 操作されたＴｒｅｇ細胞

Country Status (8)

Country Link
US (1) US20190322983A1 (enExample)
EP (1) EP3472305A4 (enExample)
JP (2) JP2019518460A (enExample)
CN (1) CN109415698A (enExample)
AU (1) AU2017285319A1 (enExample)
CA (1) CA3027546A1 (enExample)
MA (1) MA45498A (enExample)
WO (1) WO2017218850A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024539506A (ja) * 2021-10-20 2024-10-28 武田薬品工業株式会社 Ｂｃｍａを標的とする組成物及びその使用方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018069927A1 (en) * 2016-10-10 2018-04-19 The National Institute for Biotechnology in the Negev Ltd. Non-cytotoxic modified cells and use thereof
GB201714718D0 (en) 2017-09-13 2017-10-25 Autolus Ltd Cell
US20210017248A1 (en) * 2018-03-16 2021-01-21 The Regents Of The University Of California Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells
CA3105953A1 (en) 2018-07-09 2020-01-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
GB201814203D0 (en) * 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
WO2020102503A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
JP7642548B2 (ja) * 2019-02-01 2025-03-10 ケーエスキュー セラピューティクス， インコーポレイテッド 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
WO2021007396A2 (en) * 2019-07-09 2021-01-14 The Children's Mercy Hospital Engineered regulatory t cells
WO2021154882A1 (en) * 2020-01-27 2021-08-05 H. Lee Moffitt Cancer Center And Research Institute Inc. Hdac6-inhibited human regulatory t cells
US20230138428A1 (en) 2020-02-25 2023-05-04 Quell Therapeutics Limited Chimeric receptors for use in engineered cells
US12668777B2 (en) 2020-08-05 2026-06-30 Augusta University Research Institute, Inc. Chimeric antigen receptor T cells and methods of use thereof
GB202102637D0 (en) 2021-02-24 2021-04-07 Quell Therapeutics Ltd Engineered regulatory t cell
JP2024532963A (ja) 2021-04-08 2024-09-11 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ８特異的抗体コンストラクト及びその組成物
JP2026507781A (ja) 2023-01-23 2026-03-06 メディツィニシェ ホゥーシュル ハノーファー キメラ抗原受容体
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
CN120787258A (zh) 2023-02-07 2025-10-14 圭尔医疗有限公司 Treg细胞培养方法
WO2024175805A1 (en) 2023-02-24 2024-08-29 Medizinische Hochschule Hannover Chimeric antigen receptor
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194605A1 (en) 2023-03-17 2024-09-26 Quell Therapeutics Limited Treg therapy
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194355A1 (en) 2023-03-20 2024-09-26 Medizinische Hochschule Hannover Chimeric antigen receptor
US20260176598A1 (en) 2024-07-04 2026-06-25 Quell Therapeutics Limited Expression construct
GB202411558D0 (en) 2024-08-06 2024-09-18 Quell Therapeutics Ltd Culture method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009326A1 (en) * 1999-07-31 2001-02-08 The Rockefeller University Constitutively active stat proteins and their uses for identifying modulators of activity including dysproliferative cellular changes
WO2015188141A2 (en) * 2014-06-06 2015-12-10 Memorial Sloan-Kettering Cancer Ceneter Mesothelin-targeted chimeric antigen receptors and uses thereof
WO2015193406A1 (en) * 2014-06-17 2015-12-23 Cellectis Cd123 specific multi-chain chimeric antigen receptor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010531138A (ja) * 2007-06-13 2010-09-24 ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー 制御性ｔ細胞ならびに同製造および使用方法
US8658159B2 (en) * 2008-06-30 2014-02-25 Versitech Limited Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale
US11111505B2 (en) * 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009326A1 (en) * 1999-07-31 2001-02-08 The Rockefeller University Constitutively active stat proteins and their uses for identifying modulators of activity including dysproliferative cellular changes
WO2015188141A2 (en) * 2014-06-06 2015-12-10 Memorial Sloan-Kettering Cancer Ceneter Mesothelin-targeted chimeric antigen receptors and uses thereof
WO2015193406A1 (en) * 2014-06-17 2015-12-23 Cellectis Cd123 specific multi-chain chimeric antigen receptor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRISTINE VOGTENHUBER: "CONSTITUTIVELY ACTIVE STAT5B IN CD4+ T CELLS INHIBITS GRAFT-VERSUS-HOST DISEASE LETHALITY 以下備考", BLOOD, vol. VOL:116, NR:3, JPN5019005456, 22 July 2010 (2010-07-22), pages 466 - 474, ISSN: 0004616374 *
JOURNAL OF IMMUNOLOGY, vol. 171, JPN6021003667, 2003, pages 5853 - 5864, ISSN: 0004616375 *
ZHOU Q ET AL: "Mice with constitutively active STAT5b generate powerful and stable treg", AMERICAN JOURNAL OF TRANSPLANTATION, vol. 10（Supp.2), JPN6021003669, 2010, pages 10 - 41, ISSN: 0004616376 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024539506A (ja) * 2021-10-20 2024-10-28 武田薬品工業株式会社 Ｂｃｍａを標的とする組成物及びその使用方法

Also Published As

Publication number Publication date
CA3027546A1 (en) 2017-12-21
JP2022058995A (ja) 2022-04-12
EP3472305A1 (en) 2019-04-24
AU2017285319A1 (en) 2018-12-20
WO2017218850A1 (en) 2017-12-21
EP3472305A4 (en) 2020-01-15
MA45498A (fr) 2019-04-24
CN109415698A (zh) 2019-03-01
US20190322983A1 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
JP2022058995A (ja) 操作されたＴｒｅｇ細胞
Yi et al. The adaptor TRAF3 restrains the lineage determination of thymic regulatory T cells by modulating signaling via the receptor for IL-2
Pedros et al. Disrupted regulatory T cell homeostasis in inflammatory bowel diseases
Solé et al. AT follicular helper cell origin for T regulatory type 1 cells
WO2020057666A1 (zh) 表达有嵌合受体的t细胞
Cianciotti et al. TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells
CN111601882A (zh) 工程化的免疫细胞的应用和生产
Bacchetta et al. Thymic origins of autoimmunity—lessons from inborn errors of immunity
Koenig et al. NFATc1/αA and blimp-1 support the follicular and effector phenotype of Tregs
Russell et al. Lrp10 suppresses IL7R limiting CD8 T cell homeostatic expansion and anti-tumor immunity
WO2025030118A1 (en) Gene editing methods for modulating expression of id-3, an inhibitor of dna-binding transcription factors, thereby affecting t-cell function
Liu et al. The transcription factor EHF promotes the maturation and immunosuppression of conventional dendritic cells
US20190376030A1 (en) Regulatory t cell populations
US20200095549A1 (en) Method for inducing regulatory t cell
Duhan et al. FcRγ-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity
Lee et al. RORα enforces stability of the T-helper-17 cell effector program
Habrylo The Decoy Receptor IL-1R2 Attenuates Treg Activation in Tumors
Xia The Maintenance of CD4 and CD8 T Cell Response to Persistent Antigens
Orangi The role of innate lymphoid cells in steatohepatitis and liver fibrosis
Nixon Tissue-Resident Innate Immunity in Health and Cancer
Dave A Noncanonical Role of T Follicular Helper Cells in Promoting Peripheral Tolerance by Supporting T Regulatory Cells
Lam Developing next-generation regulatory T cell therapeutics
Kuchroo The role of PD-1 in modulating T cell responses in autoimmunity and cancer
Giraud et al. Transcriptional control of IL-2 sensing by Foxo1 dictates neonatal Treg homeostasis
Cvetkovski Transcriptional control of tissue-resident memory T cell generation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200615

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220215

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220215

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220222

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220224

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220303